These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15963098)

  • 1. Suboptimal choices and dosing of statins at start of therapy.
    Mantel-Teeuwisse AK; Klungel OH; Schalekamp T; Verschuren WM; Porsius AJ; de Boer A
    Br J Clin Pharmacol; 2005 Jul; 60(1):83-9. PubMed ID: 15963098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.
    Devold HM; Molden E; Skurtveit S; Furu K
    Br J Clin Pharmacol; 2009 Feb; 67(2):234-41. PubMed ID: 19220274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study.
    Geleedst-De Vooght M; Maitland-van der Zee AH; Schalekamp T; Mantel-Teeuwisse A; Jansen P
    Drugs Aging; 2010 Jul; 27(7):589-96. PubMed ID: 20583852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.
    Saw J; Brennan DM; Steinhubl SR; Bhatt DL; Mak KH; Fox K; Topol EJ;
    J Am Coll Cardiol; 2007 Jul; 50(4):291-5. PubMed ID: 17659194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
    Saw J; Steinhubl SR; Berger PB; Kereiakes DJ; Serebruany VL; Brennan D; Topol EJ;
    Circulation; 2003 Aug; 108(8):921-4. PubMed ID: 12925453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myonecrosis after elective percutaneous coronary intervention: effect of clopidogrel-statin interaction.
    Gulec S; Ozdol C; Rahimov U; Atmaca Y; Kumbasar D; Erol C
    J Invasive Cardiol; 2005 Nov; 17(11):589-93. PubMed ID: 16264203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.
    Bakhai A; Rigney U; Hollis S; Emmas C
    Pharmacoepidemiol Drug Saf; 2012 May; 21(5):485-93. PubMed ID: 22237927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
    Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement.
    Trenk D; Hochholzer W; Frundi D; Stratz C; Valina CM; Bestehorn HP; Büttner HJ; Neumann FJ
    Thromb Haemost; 2008 Jan; 99(1):174-81. PubMed ID: 18217151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
    Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
    Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
    Neuvonen PJ; Backman JT; Niemi M
    Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.
    Zhou YT; Yu LS; Zeng S; Huang YW; Xu HM; Zhou Q
    Ther Clin Risk Manag; 2014; 10():17-26. PubMed ID: 24379677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study.
    Hartz I; Sakshaug S; Furu K; Engeland A; Eggen AE; Njølstad I; Skurtveit S
    BMC Clin Pharmacol; 2007 Dec; 7():14. PubMed ID: 18053228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.
    Milner E; Ainsworth M; Gleaton M; Bookstaver D
    J Clin Pharm Ther; 2022 May; 47(5):668-675. PubMed ID: 35032137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.
    Chauvin B; Drouot S; Barrail-Tran A; Taburet AM
    Clin Pharmacokinet; 2013 Oct; 52(10):815-31. PubMed ID: 23703578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
    Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
    Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of incident diabetes among patients treated with statins: population based study.
    Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM
    BMJ; 2013 May; 346():f2610. PubMed ID: 23704171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.